{
    "info": {
        "nct_id": "NCT03684980",
        "official_title": "LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma",
        "inclusion_criteria": "Arm A:\n\n* Histologically documented B-cell non-Hodgkin\"s lymphoma involving the brain, spinal cord, and/or leptomeningeal space.\n\n  °Patients in whom the type of lymphoma could not be determined or is unknown (e.g., not enough tissue for further analysis) are assumed to have a B cell lymphoma and are eligible\n* Patients with parenchymal lesions must have received no more than two cycles of treatment for treatment of CNS lymphoma or have unequivocal evidence of disease progression on imaging (MRI of the brain/spine or CT head) 28 days prior to study registration. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings must be consistent with CSF disease 28 days prior to study registration (at the discretion of the investigator).\n* Patients who have already received two doses of treatment of CNS lymphoma are eligible for enrollment.\n* (Arm A only) as long as they are planned for at least 6 additional doses of methotrexate. Patients must not have evidence of systemic non-Hodgkin lymphoma requiring active treatment.\n* Men and woman must be at least 18 years of age on the day of consenting to the study.\n* Patients must have a Karnofsky Performance Status (KPS) ≥ 50 (See Appendix 2).\n* Patients must be willing and able to comply with scheduled visits, treatment plan, and laboratory tests.\n* Patients must have adequate bone marrow and organ function shown by:\n\n  * Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L;\n  * Platelets ≥ 100 x 10^9/L and no platelet transfusion within the past 28 days prior to study registration;\n  * Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cells (RBC) transfusion within the past 28 days prior to study registration;\n  * International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal;\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal;\n  * Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome;\n  * CrCl ≥ 60 mL/min using the Cockcroft-Gault equation. Men: CrCl (min/mL) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL) Women: CrCl (mL/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL)\n* Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.\n* Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry.\n* Patients must be able to tolerate MRI/CT scans.\n* Patients must be able to tolerate lumbar puncture and/or Ommaya taps.\n* Participants must have recovered to grade 1 toxicity from prior therapy. NOTE: Patients who have initiated and received up to two cycles of treatment will NOT be excluded from study Arm A as long as all pretreatment assessments have been completed within 28 days of trial initiation.\n\nArms B and D:\n\n* Histologically documented B-cell non-Hodgkin's lymphoma involving the brain, spinal cord, and/or leptomeningeal space\n\n  ° Patients in whom the type of lymphoma could not be determined or is unknown (e.g., not enough tissue for further analysis) are assumed to have a B cell lymphoma and are eligible\n* Patients must be treatment naïve or have unequivocal evidence of disease progression on imaging (MRI of the brain/spine or CT head) 28 days prior to initiation of MTX. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings must be consistent with CSF disease 28 days prior to initiation of MTX. (at the discretion of the investigator)\n* Patients must not have evidence of systemic non-Hodgkin lymphoma requiring active treatment\n* Men and woman must be at least 18 years of age on the day of consenting to the study\n* Patients must have a Karnofsky Performance Status (KPS) >/= 70 or >/= 50 if KPS is due to a neurologic deficit attributed to active disease\n* Patients must be willing and able to comply with scheduled visits, treatment plan, and laboratory tests\n* Patients must have adequate bone marrow and organ function shown by:\n\n  * Absolute neutrophil count (ANC) >/= 1.0 x 10^9/L\n  * Platelets >/= 100 x 10^9/L and no platelet transfusion within the past 28 days prior to study registration\n  * Hemoglobin (Hgb) >/= 8g/dL and no red blood cells (RBC) transfusion within the past 28 days prior to study registration\n  * International Normalized Ratio (INR) </= 1.5 and PTT (aPTT) </= 1.5 times the upper limit of normal\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) </= 3 times the upper limit of normal\n  * Serum bilirubin </= 1.5 times the upper limit of normal; or total bilirubin </= 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome\n  * CrCl >/= 60 mL/min using the Cockcroft-Gault equation Men: CrCl (min/mL) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL) Women: CrCl (mL/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL)\n* Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.\n* Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry\n* Patients must be able to tolerate MRI/CT scans\n* Patients must be able to tolerate lumbar puncture and/or Ommaya taps\n* Participants must have recovered to grade 1 toxicity from prior therapy\n* Patients with ocular manifestation of systemic lymphoma are allowed if repeat ophthalmologic exam is planned for the end of therapy. If ocular disease remains present, ocular-directed therapy may be administered after treatment with methotrexate.\n* Patients must be able to tolerate po hydration (Arm D only)\n\nNOTE: Prior autologous stem cell transplant as well as prior radiation to the CNS does NOT prevent patients from enrollment into the trial.\n\nArm Outpatient MTX Therapy in times of COVID-19:\n\n* Patients eligible for inclusion in this arm must be eligible for inpatient MTX administration for treatment of CNS lymphoma. Patients should have received prior MTX therapy without major adverse events.\n* Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry.\n\nArm E:\n\n* Documented history of CNS lymphoma, appropriate for standard of care inpatient MTX administration as determined by their treating physician\n* Men and woman must be at least 18 years of age on the day of consenting to the study.\n* Patients must be willing and able to comply with scheduled visits, treatment plan, and laboratory tests.\n* Patients must meet at least ONE of the following additional criteria\n\n  * MTX >100 nmol/L ≥ 72 hours after initiation of MTX\n  * History of prolonged MTX clearance (≥ 72 hours) after prior MTX administration of equal or higher dose (g/m2)\n  * CrCl < 60 ml/min calculated by Cockroft-Gault equation oHistory of MTX-related toxicity, CTCAE v5 grade 2 or higher (must have recovered to a grade 1 toxicity)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "Arms A, B and D:\n\n* Patient with SCNSL requiring treatment for extra-CNS disease are excluded.\n* Patient concurrently using other approved or investigational antineoplastic agents.\n* Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosoureas or mitomycin-C prior to starting the study drug, or the patient has not recovered from the side effects of such therapy. Exceptions are allowed for rituximab and methotrexate for patients enrolling Arm A as long as patients have recovered from side effects.\n* Patient has received external beam radiation therapy to the CNS within 28 days of the first dose of the study drug.\n* Patient has an active concurrent malignancy requiring active therapy.\n* The patient has been treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug.\n* Patient weighs <40kg\n* Patient is allergic to components of the study drug.\n* Patient is known to have human immunodeficiency virus (HIV) infection.\n* Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests.\n* Severe, active medical co-morbidity such as unstable angina and/or congestive heart failure, coronary artery disease, significant abnormalities on electrocardiogram (EKG), uncontrolled or symptomatic arrhythmias or valvular disease; active infection, severe chronic obstructive pulmonary disease or other respiratory illness, hepatic insufficiency, known pre-existing immunodeficiency as seen in organ transplant recipients, renal failure with CrCl <60 mL/min.\n* Patient has a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject\"s safety or put the study outcomes at undue risk.\n* Patient has large pleural or ascetic fluid collection.\n* Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.\n* Prior severe allergic reaction to any of the study drugs that cannot be resolved with medication.\n* Patient has undergone prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion).\n\nArm Outpatient MTX Therapy in times of COVID-19:\n\nPatients eligible for this arm must not meet any of the following criteria:\n\n* Patients with SCNSL requiring treatment for extra-CNS disease are excluded.\n* Patients weighing <40kg\n* Inadequate bone marrow and organ function shown by:\n\n  * Absolute neutrophil count (ANC) </= 0.5 x 10^9/L\n  * Platelets </= 75 x 10^9/L\n  * Hemoglobin (Hgb) </= 8 g/dL\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >/= 3 times the upper limit of normal\n  * Serum bilirubin >/= 1.5 times the upper limit of normal; or total bilirubin >/= 3 times the upper limit of normal with direct bilirubin outside of the normal range in patients with well documented Gilbert Syndrome\n  * Creatinine >/= 1.3 mg/dL\n* Patients allergic to components of the study drug.\n* Patients with severe, active medical co-morbidity such as unstable angina and/or congestive heart failure, coronary artery disease, significant abnormalities on electrocardiogram (EKG), uncontrolled or symptomatic arrhythmias or valvular disease; active infection, severe chronic obstructive pulmonary disease or other respiratory illness, hepatic insufficiency, known pre-existing immunodeficiency as seen in organ transplant recipients, renal failure with creatinine >/= 1.3 mg/dL.\n* Patients with a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk\n* Patients with large pleural or ascetic fluid collection\n* Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose\n\nArm E:\n\nPatients eligible for this arm must not meet any of the following criteria:\n\n* Weight <40kg\n* Prior severe allergic reaction to methotrexate or glucarpidase that cannot be resolved withmedication.\n* Severe, active medical co-morbidity such as unstable angina and/or congestive heart failure, coronary artery disease, significant abnormalities on electrocardiogram (EKG), uncontrolled or symptomatic arrhythmias or valvular disease; active uncontrolled infection, severe chronic obstructive pulmonary disease or other respiratory illness, hepatic insufficiency\n* Patient has a life-threatening illness, medical condition, or organ system dysfunctionthat, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk.\n* Presence of large pleural or ascetic fluid collection.\n* Treatment with MTX dose greater than 8 g/m2",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Participants must have recovered to grade 1 toxicity from prior therapy",
            "criterions": [
                {
                    "exact_snippets": "recovered to grade 1 toxicity from prior therapy",
                    "criterion": "toxicity from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin (Hgb) >/= 8g/dL and no red blood cells (RBC) transfusion within the past 28 days prior to study registration",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin (Hgb) >/= 8g/dL",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no red blood cells (RBC) transfusion within the past 28 days prior to study registration",
                    "criterion": "red blood cells (RBC) transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within the past 28 days prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men and woman must be at least 18 years of age on the day of consenting to the study.",
            "criterions": [
                {
                    "exact_snippets": "Men and woman must be at least 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L;",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry.",
            "criterions": [
                {
                    "exact_snippets": "Female subjects of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative plasma pregnancy test upon study entry",
                    "criterion": "plasma pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "upon study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.",
            "criterions": [
                {
                    "exact_snippets": "Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug.",
                    "criterion": "women of reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use highly effective birth control",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of birth control use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of therapy"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.",
                    "criterion": "sexually active men",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use highly effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of therapy"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be willing and able to comply with scheduled visits, treatment plan, and laboratory tests",
            "criterions": [
                {
                    "exact_snippets": "willing and able to comply with scheduled visits",
                    "criterion": "compliance with scheduled visits",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to comply with ... treatment plan",
                    "criterion": "compliance with treatment plan",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to comply with ... laboratory tests",
                    "criterion": "compliance with laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to tolerate MRI/CT scans.",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to tolerate MRI/CT scans.",
                    "criterion": "tolerance to MRI/CT scans",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men and woman must be at least 18 years of age on the day of consenting to the study.",
            "criterions": [
                {
                    "exact_snippets": "Men and woman must be at least 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically documented B-cell non-Hodgkin\"s lymphoma involving the brain, spinal cord, and/or leptomeningeal space.",
            "criterions": [
                {
                    "exact_snippets": "Histologically documented B-cell non-Hodgkin\"s lymphoma",
                    "criterion": "B-cell non-Hodgkin's lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "involving the brain, spinal cord, and/or leptomeningeal space",
                    "criterion": "lymphoma involvement sites",
                    "requirements": [
                        {
                            "requirement_type": "anatomic involvement",
                            "expected_value": [
                                "brain",
                                "spinal cord",
                                "leptomeningeal space"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have evidence of systemic non-Hodgkin lymphoma requiring active treatment",
            "criterions": [
                {
                    "exact_snippets": "must not have evidence of systemic non-Hodgkin lymphoma requiring active treatment",
                    "criterion": "systemic non-Hodgkin lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have recovered to grade 1 toxicity from prior therapy. NOTE: Patients who have initiated and received up to two cycles of treatment will NOT be excluded from study Arm A as long as all pretreatment assessments have been completed within 28 days of trial initiation.",
            "criterions": [
                {
                    "exact_snippets": "Participants must have recovered to grade 1 toxicity from prior therapy",
                    "criterion": "toxicity from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have initiated and received up to two cycles of treatment will NOT be excluded from study Arm A as long as all pretreatment assessments have been completed within 28 days of trial initiation",
                    "criterion": "pretreatment assessments",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be willing and able to comply with scheduled visits, treatment plan, and laboratory tests.",
            "criterions": [
                {
                    "exact_snippets": "willing and able to comply with scheduled visits",
                    "criterion": "compliance with scheduled visits",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to comply with ... treatment plan",
                    "criterion": "compliance with treatment plan",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to comply with ... laboratory tests",
                    "criterion": "compliance with laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented history of CNS lymphoma, appropriate for standard of care inpatient MTX administration as determined by their treating physician",
            "criterions": [
                {
                    "exact_snippets": "Documented history of CNS lymphoma",
                    "criterion": "CNS lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "appropriate for standard of care inpatient MTX administration as determined by their treating physician",
                    "criterion": "appropriateness for inpatient MTX administration",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "determined by treating physician",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "°Patients in whom the type of lymphoma could not be determined or is unknown (e.g., not enough tissue for further analysis) are assumed to have a B cell lymphoma and are eligible",
            "criterions": [
                {
                    "exact_snippets": "type of lymphoma could not be determined or is unknown",
                    "criterion": "type of lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "determinability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not enough tissue for further analysis",
                    "criterion": "tissue for further analysis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to tolerate lumbar puncture and/or Ommaya taps",
            "criterions": [
                {
                    "exact_snippets": "able to tolerate lumbar puncture",
                    "criterion": "lumbar puncture",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to tolerate ... Ommaya taps",
                    "criterion": "Ommaya taps",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CrCl < 60 ml/min calculated by Cockroft-Gault equation oHistory of MTX-related toxicity, CTCAE v5 grade 2 or higher (must have recovered to a grade 1 toxicity)",
            "criterions": [
                {
                    "exact_snippets": "CrCl < 60 ml/min calculated by Cockroft-Gault equation",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockroft-Gault equation"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of MTX-related toxicity, CTCAE v5 grade 2 or higher (must have recovered to a grade 1 toxicity)",
                    "criterion": "MTX-related toxicity",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE v5 grade"
                            }
                        },
                        {
                            "requirement_type": "recovery",
                            "expected_value": "must have recovered to a grade 1 toxicity"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to tolerate MRI/CT scans",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to tolerate MRI/CT scans",
                    "criterion": "tolerance to MRI/CT scans",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry.",
            "criterions": [
                {
                    "exact_snippets": "Female subjects of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative plasma pregnancy test upon study entry",
                    "criterion": "plasma pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "upon study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients eligible for inclusion in this arm must be eligible for inpatient MTX administration for treatment of CNS lymphoma. Patients should have received prior MTX therapy without major adverse events.",
            "criterions": [
                {
                    "exact_snippets": "eligible for inpatient MTX administration for treatment of CNS lymphoma",
                    "criterion": "inpatient MTX administration eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "received prior MTX therapy",
                    "criterion": "prior MTX therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of administration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without major adverse events",
                    "criterion": "major adverse events from prior MTX therapy",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >/= 1.0 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >/= 1.0 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be treatment naïve or have unequivocal evidence of disease progression on imaging (MRI of the brain/spine or CT head) 28 days prior to initiation of MTX. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings must be consistent with CSF disease 28 days prior to initiation of MTX. (at the discretion of the investigator)",
            "criterions": [
                {
                    "exact_snippets": "Patients must be treatment naïve or have unequivocal evidence of disease progression on imaging (MRI of the brain/spine or CT head) 28 days prior to initiation of MTX.",
                    "criterion": "prior treatment status or disease progression",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treatment naïve"
                        },
                        {
                            "requirement_type": "disease progression evidence",
                            "expected_value": "unequivocal evidence of disease progression on imaging (MRI of the brain/spine or CT head) 28 days prior to initiation of MTX"
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings must be consistent with CSF disease 28 days prior to initiation of MTX.",
                    "criterion": "leptomeningeal disease documentation",
                    "requirements": [
                        {
                            "requirement_type": "CSF cytology",
                            "expected_value": "document lymphoma cells"
                        },
                        {
                            "requirement_type": "imaging findings",
                            "expected_value": "consistent with CSF disease 28 days prior to initiation of MTX"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome;",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin ≤ 1.5 times the upper limit of normal",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "patients with well documented Gilbert Syndrome"
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within the normal range"
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "patients with well documented Gilbert Syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with parenchymal lesions must have received no more than two cycles of treatment for treatment of CNS lymphoma or have unequivocal evidence of disease progression on imaging (MRI of the brain/spine or CT head) 28 days prior to study registration. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings must be consistent with CSF disease 28 days prior to study registration (at the discretion of the investigator).",
            "criterions": [
                {
                    "exact_snippets": "Patients with parenchymal lesions must have received no more than two cycles of treatment for treatment of CNS lymphoma",
                    "criterion": "number of prior CNS lymphoma treatment cycles (parenchymal lesions)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "or have unequivocal evidence of disease progression on imaging (MRI of the brain/spine or CT head) 28 days prior to study registration",
                    "criterion": "disease progression on imaging (parenchymal lesions)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 28 days prior to study registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells",
                    "criterion": "CSF cytology (leptomeningeal disease only)",
                    "requirements": [
                        {
                            "requirement_type": "presence of lymphoma cells",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 28 days prior to study registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "and/or imaging findings must be consistent with CSF disease 28 days prior to study registration (at the discretion of the investigator)",
                    "criterion": "imaging findings consistent with CSF disease (leptomeningeal disease only)",
                    "requirements": [
                        {
                            "requirement_type": "consistency with CSF disease",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 28 days prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International Normalized Ratio (INR) </= 1.5 and PTT (aPTT) </= 1.5 times the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "International Normalized Ratio (INR) </= 1.5",
                    "criterion": "International Normalized Ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PTT (aPTT) </= 1.5 times the upper limit of normal",
                    "criterion": "PTT (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry",
            "criterions": [
                {
                    "exact_snippets": "Female subjects of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative plasma pregnancy test upon study entry",
                    "criterion": "plasma pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "upon study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "° Patients in whom the type of lymphoma could not be determined or is unknown (e.g., not enough tissue for further analysis) are assumed to have a B cell lymphoma and are eligible",
            "criterions": [
                {
                    "exact_snippets": "type of lymphoma could not be determined or is unknown",
                    "criterion": "type of lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "determinability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "known status",
                            "expected_value": "unknown"
                        }
                    ]
                },
                {
                    "exact_snippets": "not enough tissue for further analysis",
                    "criterion": "tissue for further analysis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "not enough"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cells (RBC) transfusion within the past 28 days prior to study registration;",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin (Hgb) ≥ 8 g/dL",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no red blood cells (RBC) transfusion within the past 28 days prior to study registration",
                    "criterion": "red blood cells (RBC) transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": "no transfusion within 28 days prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Arm Outpatient MTX Therapy in times of COVID-19:",
            "criterions": [
                {
                    "exact_snippets": "Outpatient MTX Therapy",
                    "criterion": "MTX therapy setting",
                    "requirements": [
                        {
                            "requirement_type": "setting",
                            "expected_value": "outpatient"
                        }
                    ]
                },
                {
                    "exact_snippets": "in times of COVID-19",
                    "criterion": "COVID-19 pandemic period",
                    "requirements": [
                        {
                            "requirement_type": "time period",
                            "expected_value": "during COVID-19 pandemic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be willing and able to comply with scheduled visits, treatment plan, and laboratory tests.",
            "criterions": [
                {
                    "exact_snippets": "willing and able to comply with scheduled visits",
                    "criterion": "compliance with scheduled visits",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to comply with ... treatment plan",
                    "criterion": "compliance with treatment plan",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to comply with ... laboratory tests",
                    "criterion": "compliance with laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with ocular manifestation of systemic lymphoma are allowed if repeat ophthalmologic exam is planned for the end of therapy. If ocular disease remains present, ocular-directed therapy may be administered after treatment with methotrexate.",
            "criterions": [
                {
                    "exact_snippets": "Patients with ocular manifestation of systemic lymphoma are allowed",
                    "criterion": "ocular manifestation of systemic lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "repeat ophthalmologic exam is planned for the end of therapy",
                    "criterion": "repeat ophthalmologic exam at end of therapy",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If ocular disease remains present, ocular-directed therapy may be administered after treatment with methotrexate",
                    "criterion": "ocular-directed therapy after methotrexate",
                    "requirements": [
                        {
                            "requirement_type": "administration",
                            "expected_value": "may be administered if ocular disease remains present after methotrexate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "NOTE: Prior autologous stem cell transplant as well as prior radiation to the CNS does NOT prevent patients from enrollment into the trial.",
            "criterions": [
                {
                    "exact_snippets": "Prior autologous stem cell transplant ... does NOT prevent patients from enrollment into the trial.",
                    "criterion": "prior autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exclusion from enrollment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior radiation to the CNS does NOT prevent patients from enrollment into the trial.",
                    "criterion": "prior radiation to the CNS",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exclusion from enrollment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a Karnofsky Performance Status (KPS) >/= 70 or >/= 50 if KPS is due to a neurologic deficit attributed to active disease",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky Performance Status (KPS) >/= 70",
                    "criterion": "Karnofsky Performance Status (KPS)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": ">/= 50 if KPS is due to a neurologic deficit attributed to active disease",
                    "criterion": "Karnofsky Performance Status (KPS) due to neurologic deficit attributed to active disease",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "neurologic deficit attributed to active disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 100 x 10^9/L and no platelet transfusion within the past 28 days prior to study registration;",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 100 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no platelet transfusion within the past 28 days prior to study registration",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within the past 28 days prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have adequate bone marrow and organ function shown by:",
            "criterions": [
                {
                    "exact_snippets": "adequate bone marrow and organ function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate bone marrow and organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have already received two doses of treatment of CNS lymphoma are eligible for enrollment.",
            "criterions": [
                {
                    "exact_snippets": "already received two doses of treatment of CNS lymphoma",
                    "criterion": "treatment of CNS lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "number of doses received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "doses"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CrCl >/= 60 mL/min using the Cockcroft-Gault equation Men: CrCl (min/mL) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL) Women: CrCl (mL/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL)",
            "criterions": [
                {
                    "exact_snippets": "CrCl >/= 60 mL/min using the Cockcroft-Gault equation",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Arm A only) as long as they are planned for at least 6 additional doses of methotrexate. Patients must not have evidence of systemic non-Hodgkin lymphoma requiring active treatment.",
            "criterions": [
                {
                    "exact_snippets": "planned for at least 6 additional doses of methotrexate",
                    "criterion": "planned methotrexate doses",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "doses"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have evidence of systemic non-Hodgkin lymphoma requiring active treatment",
                    "criterion": "systemic non-Hodgkin lymphoma requiring active treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin </= 1.5 times the upper limit of normal; or total bilirubin </= 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin </= 1.5 times the upper limit of normal",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin </= 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "patients with well documented Gilbert Syndrome"
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within the normal range"
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "patients with well documented Gilbert Syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically documented B-cell non-Hodgkin's lymphoma involving the brain, spinal cord, and/or leptomeningeal space",
            "criterions": [
                {
                    "exact_snippets": "Histologically documented B-cell non-Hodgkin's lymphoma",
                    "criterion": "B-cell non-Hodgkin's lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "involving the brain, spinal cord, and/or leptomeningeal space",
                    "criterion": "disease involvement sites",
                    "requirements": [
                        {
                            "requirement_type": "anatomic location",
                            "expected_value": [
                                "brain",
                                "spinal cord",
                                "leptomeningeal space"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a Karnofsky Performance Status (KPS) ≥ 50 (See Appendix 2).",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky Performance Status (KPS) ≥ 50",
                    "criterion": "Karnofsky Performance Status (KPS)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of prolonged MTX clearance (≥ 72 hours) after prior MTX administration of equal or higher dose (g/m2)",
            "criterions": [
                {
                    "exact_snippets": "History of prolonged MTX clearance (≥ 72 hours) after prior MTX administration of equal or higher dose (g/m2)",
                    "criterion": "MTX clearance",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 72,
                                "unit": "hours"
                            }
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior MTX administration of equal or higher dose (g/m2)",
                    "criterion": "prior MTX administration dose",
                    "requirements": [
                        {
                            "requirement_type": "dose_comparison",
                            "expected_value": "equal or higher dose (g/m2)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CrCl ≥ 60 mL/min using the Cockcroft-Gault equation. Men: CrCl (min/mL) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL) Women: CrCl (mL/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL)",
            "criterions": [
                {
                    "exact_snippets": "CrCl ≥ 60 mL/min using the Cockcroft-Gault equation",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men and woman must be at least 18 years of age on the day of consenting to the study",
            "criterions": [
                {
                    "exact_snippets": "Men and woman must be at least 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal;",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 3 times the upper limit of normal",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* MTX >100 nmol/L ≥ 72 hours after initiation of MTX",
            "criterions": [
                {
                    "exact_snippets": "MTX >100 nmol/L ≥ 72 hours after initiation of MTX",
                    "criterion": "MTX concentration",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "nmol/L"
                            }
                        },
                        {
                            "requirement_type": "time since initiation of MTX",
                            "expected_value": {
                                "operator": ">=",
                                "value": 72,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must meet at least ONE of the following additional criteria",
            "criterions": [
                {
                    "exact_snippets": "Patients must meet at least ONE of the following additional criteria",
                    "criterion": "additional criteria (unspecified)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.",
            "criterions": [
                {
                    "exact_snippets": "Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug.",
                    "criterion": "women of reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use highly effective birth control",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of birth control use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of therapy"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.",
                    "criterion": "sexually active men",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use highly effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of therapy"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) </= 3 times the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... </= 3 times the upper limit of normal",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) </= 3 times the upper limit of normal",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to tolerate lumbar puncture and/or Ommaya taps.",
            "criterions": [
                {
                    "exact_snippets": "able to tolerate lumbar puncture",
                    "criterion": "lumbar puncture",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to tolerate ... Ommaya taps",
                    "criterion": "Ommaya taps",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have adequate bone marrow and organ function shown by:",
            "criterions": [
                {
                    "exact_snippets": "adequate bone marrow and organ function",
                    "criterion": "bone marrow and organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to tolerate po hydration (Arm D only)",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to tolerate po hydration (Arm D only)",
                    "criterion": "oral hydration tolerance",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment arm",
                            "expected_value": "Arm D only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >/= 100 x 10^9/L and no platelet transfusion within the past 28 days prior to study registration",
            "criterions": [
                {
                    "exact_snippets": "Platelets >/= 100 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no platelet transfusion within the past 28 days prior to study registration",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within the past 28 days prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal;",
            "criterions": [
                {
                    "exact_snippets": "International Normalized Ratio (INR) ≤ 1.5",
                    "criterion": "International Normalized Ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PTT (aPTT) ≤ 1.5 times the upper limit of normal",
                    "criterion": "PTT (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patient has an active concurrent malignancy requiring active therapy.",
            "criterions": [
                {
                    "exact_snippets": "active concurrent malignancy requiring active therapy",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior severe allergic reaction to methotrexate or glucarpidase that cannot be resolved withmedication.",
            "criterions": [
                {
                    "exact_snippets": "Prior severe allergic reaction to methotrexate",
                    "criterion": "allergic reaction to methotrexate",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": "prior"
                        },
                        {
                            "requirement_type": "resolvability with medication",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior severe allergic reaction to ... glucarpidase",
                    "criterion": "allergic reaction to glucarpidase",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": "prior"
                        },
                        {
                            "requirement_type": "resolvability with medication",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient concurrently using other approved or investigational antineoplastic agents.",
            "criterions": [
                {
                    "exact_snippets": "Patient concurrently using other approved or investigational antineoplastic agents",
                    "criterion": "concurrent use of other antineoplastic agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent type",
                            "expected_value": [
                                "approved",
                                "investigational"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient weighs <40kg",
            "criterions": [
                {
                    "exact_snippets": "Patient weighs <40kg",
                    "criterion": "weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Arm Outpatient MTX Therapy in times of COVID-19:",
            "criterions": [
                {
                    "exact_snippets": "Outpatient MTX Therapy",
                    "criterion": "MTX therapy setting",
                    "requirements": [
                        {
                            "requirement_type": "setting",
                            "expected_value": "outpatient"
                        }
                    ]
                },
                {
                    "exact_snippets": "in times of COVID-19",
                    "criterion": "COVID-19 pandemic period",
                    "requirements": [
                        {
                            "requirement_type": "time period",
                            "expected_value": "during COVID-19 pandemic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin >/= 1.5 times the upper limit of normal; or total bilirubin >/= 3 times the upper limit of normal with direct bilirubin outside of the normal range in patients with well documented Gilbert Syndrome",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin >/= 1.5 times the upper limit of normal",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin >/= 3 times the upper limit of normal with direct bilirubin outside of the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin outside of the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "outside of the normal range"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine >/= 1.3 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Creatinine >/= 1.3 mg/dL",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.3,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with SCNSL requiring treatment for extra-CNS disease are excluded.",
            "criterions": [
                {
                    "exact_snippets": "Patients with SCNSL requiring treatment for extra-CNS disease are excluded.",
                    "criterion": "SCNSL (secondary central nervous system lymphoma) with extra-CNS disease requiring treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe, active medical co-morbidity such as unstable angina and/or congestive heart failure, coronary artery disease, significant abnormalities on electrocardiogram (EKG), uncontrolled or symptomatic arrhythmias or valvular disease; active infection, severe chronic obstructive pulmonary disease or other respiratory illness, hepatic insufficiency, known pre-existing immunodeficiency as seen in organ transplant recipients, renal failure with CrCl <60 mL/min.",
            "criterions": [
                {
                    "exact_snippets": "Severe, active medical co-morbidity such as unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary artery disease",
                    "criterion": "coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant abnormalities on electrocardiogram (EKG)",
                    "criterion": "abnormalities on electrocardiogram (EKG)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled or symptomatic arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "valvular disease",
                    "criterion": "valvular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe chronic obstructive pulmonary disease",
                    "criterion": "chronic obstructive pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "other respiratory illness",
                    "criterion": "respiratory illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatic insufficiency",
                    "criterion": "hepatic insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known pre-existing immunodeficiency as seen in organ transplant recipients",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "pre-existence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "organ transplant"
                        }
                    ]
                },
                {
                    "exact_snippets": "renal failure with CrCl <60 mL/min",
                    "criterion": "renal failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "creatinine clearance",
                            "expected_value": {
                                "operator": "<",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Weight <40kg",
            "criterions": [
                {
                    "exact_snippets": "Weight <40kg",
                    "criterion": "weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is allergic to components of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "Patient is allergic to components of the study drug",
                    "criterion": "allergy to study drug components",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >/= 3 times the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... >/= 3 times the upper limit of normal",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ... >/= 3 times the upper limit of normal",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets </= 75 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Platelets </= 75 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 75,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) </= 0.5 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) </= 0.5 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has large pleural or ascetic fluid collection.",
            "criterions": [
                {
                    "exact_snippets": "large pleural or ascetic fluid collection",
                    "criterion": "pleural fluid collection",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": "large"
                        }
                    ]
                },
                {
                    "exact_snippets": "large pleural or ascetic fluid collection",
                    "criterion": "ascetic fluid collection",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": "large"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The patient has been treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug",
                    "criterion": "treatment with radio- or toxin-immunoconjugates",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 70,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relative_to_event",
                            "expected_value": "first dose of the study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential ... not willing/able to use medically acceptable forms of contraception",
                    "criterion": "women of childbearing potential contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness/ability to use contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "men who are sexually active and not willing/able to use medically acceptable forms of contraception",
                    "criterion": "sexually active men contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness/ability to use contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug",
                    "criterion": "women of reproductive potential contraception use",
                    "requirements": [
                        {
                            "requirement_type": "use of highly effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during therapy"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose",
                    "criterion": "sexually active men contraception use (highly effective)",
                    "requirements": [
                        {
                            "requirement_type": "use of highly effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during therapy"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with severe, active medical co-morbidity such as unstable angina and/or congestive heart failure, coronary artery disease, significant abnormalities on electrocardiogram (EKG), uncontrolled or symptomatic arrhythmias or valvular disease; active infection, severe chronic obstructive pulmonary disease or other respiratory illness, hepatic insufficiency, known pre-existing immunodeficiency as seen in organ transplant recipients, renal failure with creatinine >/= 1.3 mg/dL.",
            "criterions": [
                {
                    "exact_snippets": "severe, active medical co-morbidity such as unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary artery disease",
                    "criterion": "coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant abnormalities on electrocardiogram (EKG)",
                    "criterion": "abnormalities on electrocardiogram (EKG)",
                    "requirements": [
                        {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled or symptomatic arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "valvular disease",
                    "criterion": "valvular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe chronic obstructive pulmonary disease",
                    "criterion": "chronic obstructive pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "other respiratory illness",
                    "criterion": "respiratory illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatic insufficiency",
                    "criterion": "hepatic insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known pre-existing immunodeficiency as seen in organ transplant recipients",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "pre-existence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "organ transplant"
                        }
                    ]
                },
                {
                    "exact_snippets": "renal failure with creatinine >/= 1.3 mg/dL",
                    "criterion": "renal failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine >/= 1.3 mg/dL",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.3,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe, active medical co-morbidity such as unstable angina and/or congestive heart failure, coronary artery disease, significant abnormalities on electrocardiogram (EKG), uncontrolled or symptomatic arrhythmias or valvular disease; active uncontrolled infection, severe chronic obstructive pulmonary disease or other respiratory illness, hepatic insufficiency",
            "criterions": [
                {
                    "exact_snippets": "Severe, active medical co-morbidity such as unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary artery disease",
                    "criterion": "coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant abnormalities on electrocardiogram (EKG)",
                    "criterion": "abnormalities on electrocardiogram (EKG)",
                    "requirements": [
                        {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled or symptomatic arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "valvular disease",
                    "criterion": "valvular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe chronic obstructive pulmonary disease",
                    "criterion": "chronic obstructive pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "other respiratory illness",
                    "criterion": "respiratory illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatic insufficiency",
                    "criterion": "hepatic insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient with SCNSL requiring treatment for extra-CNS disease are excluded.",
            "criterions": [
                {
                    "exact_snippets": "Patient with SCNSL requiring treatment for extra-CNS disease are excluded.",
                    "criterion": "SCNSL (secondary central nervous system lymphoma) with extra-CNS disease requiring treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with MTX dose greater than 8 g/m2",
            "criterions": [
                {
                    "exact_snippets": "Treatment with MTX dose greater than 8 g/m2",
                    "criterion": "MTX dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "g/m2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with large pleural or ascetic fluid collection",
            "criterions": [
                {
                    "exact_snippets": "large pleural ... fluid collection",
                    "criterion": "pleural fluid collection",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": "large"
                        }
                    ]
                },
                {
                    "exact_snippets": "large ... ascetic fluid collection",
                    "criterion": "ascitic fluid collection",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": "large"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential ... not willing/able to use medically acceptable forms of contraception",
                    "criterion": "contraception use in women of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "willingness/ability to use contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "men who are sexually active and not willing/able to use medically acceptable forms of contraception",
                    "criterion": "contraception use in sexually active men",
                    "requirements": [
                        {
                            "requirement_type": "willingness/ability to use contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has received external beam radiation therapy to the CNS within 28 days of the first dose of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "received external beam radiation therapy to the CNS within 28 days of the first dose of the study drug",
                    "criterion": "external beam radiation therapy to the CNS",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relative_to_event",
                            "expected_value": "first dose of the study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients allergic to components of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "Patients allergic to components of the study drug",
                    "criterion": "allergy to components of the study drug",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is known to have human immunodeficiency virus (HIV) infection.",
            "criterions": [
                {
                    "exact_snippets": "Patient is known to have human immunodeficiency virus (HIV) infection.",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests.",
            "criterions": [
                {
                    "exact_snippets": "history of active or chronic infection with hepatitis C virus (HCV) ... as determined by serologic tests",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history of infection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "infection status",
                            "expected_value": [
                                "active",
                                "chronic"
                            ]
                        },
                        {
                            "requirement_type": "determination method",
                            "expected_value": "serologic tests"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of active or chronic infection with ... hepatitis B virus (HBV) as determined by serologic tests",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history of infection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "infection status",
                            "expected_value": [
                                "active",
                                "chronic"
                            ]
                        },
                        {
                            "requirement_type": "determination method",
                            "expected_value": "serologic tests"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inadequate bone marrow and organ function shown by:",
            "criterions": [
                {
                    "exact_snippets": "Inadequate bone marrow and organ function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Inadequate bone marrow and organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosoureas or mitomycin-C prior to starting the study drug, or the patient has not recovered from the side effects of such therapy. Exceptions are allowed for rituximab and methotrexate for patients enrolling Arm A as long as patients have recovered from side effects.",
            "criterions": [
                {
                    "exact_snippets": "Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosoureas or mitomycin-C prior to starting the study drug",
                    "criterion": "prior anticancer therapy (chemotherapy, monoclonal antibodies, targeted therapy)",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "6 weeks for nitrosoureas or mitomycin-C prior to starting the study drug",
                    "criterion": "prior nitrosoureas or mitomycin-C therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the patient has not recovered from the side effects of such therapy",
                    "criterion": "recovery from side effects of prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery from side effects",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Exceptions are allowed for rituximab and methotrexate for patients enrolling Arm A as long as patients have recovered from side effects",
                    "criterion": "rituximab or methotrexate therapy in Arm A",
                    "requirements": [
                        {
                            "requirement_type": "recovery from side effects",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has undergone prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion).",
            "criterions": [
                {
                    "exact_snippets": "Patient has undergone prior allogenic stem cell transplant",
                    "criterion": "prior allogenic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autologous stem cell transplant is NOT an exclusion",
                    "criterion": "prior autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
            "criterions": [
                {
                    "exact_snippets": "life-threatening illness",
                    "criterion": "life-threatening illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "medical condition ... that ... could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "medical condition that could compromise safety or study outcomes",
                    "requirements": [
                        {
                            "requirement_type": "risk to safety or study outcomes",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organ system dysfunction ... that ... could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "organ system dysfunction that could compromise safety or study outcomes",
                    "requirements": [
                        {
                            "requirement_type": "risk to safety or study outcomes",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior severe allergic reaction to any of the study drugs that cannot be resolved with medication.",
            "criterions": [
                {
                    "exact_snippets": "Prior severe allergic reaction to any of the study drugs",
                    "criterion": "severe allergic reaction to study drugs",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cannot be resolved with medication",
                    "criterion": "severe allergic reaction to study drugs",
                    "requirements": [
                        {
                            "requirement_type": "resolvability with medication",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of large pleural or ascetic fluid collection.",
            "criterions": [
                {
                    "exact_snippets": "Presence of large pleural or ascetic fluid collection.",
                    "criterion": "pleural fluid collection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": "large"
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of large pleural or ascetic fluid collection.",
                    "criterion": "ascitic fluid collection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": "large"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin (Hgb) </= 8 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin (Hgb) </= 8 g/dL",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients weighing <40kg",
            "criterions": [
                {
                    "exact_snippets": "Patients weighing <40kg",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a life-threatening illness, medical condition, or organ system dysfunctionthat, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk.",
            "criterions": [
                {
                    "exact_snippets": "life-threatening illness",
                    "criterion": "life-threatening illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "medical condition",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organ system dysfunction",
                    "criterion": "organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Arm E:",
            "criterions": []
        },
        {
            "line": "Arm A:",
            "criterions": []
        },
        {
            "line": "Arms B and D:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "Patients eligible for this arm must not meet any of the following criteria:",
            "criterions": []
        },
        {
            "line": "Arm E:",
            "criterions": []
        },
        {
            "line": "Arms A, B and D:",
            "criterions": []
        },
        {
            "line": "Patients eligible for this arm must not meet any of the following criteria:",
            "criterions": []
        },
        {
            "line": "* Patient has a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject\"s safety or put the study outcomes at undue risk.",
            "criterions": [
                {
                    "exact_snippets": "life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "life-threatening illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}